SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test

详细摘要
SMMT shares plunged 20% overnight late Sunday after the FDA rejected its Ivonescimab-plus-chemotherapy application for a lung cancer indication.
Shares of Summit Therapeutics (SMMT) plunged 20% overnight late Sunday after a weekend FDA rejection, fueling fear among Capricor Therapeutics (CAPR) investors ahead of a Nov.22 decision on Deramiocel, its experimental treatment for Duchenne muscular dystrophy (DMD).
SMMT stock fell 13% last week, posting its worst weekly performance in a month, while CAPR rose 6% for its third consecutive weekly gain.
See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox
Summit announced the FDA's rejection on Sunday, one week before Capricor's Nov.22 decision deadline. The rejection covers Ivonescimab plus chemotherapy for patients with advanced, EGFR-mutated non-small cell lung cancer whose disease progressed after an EGFR-targeted treatment.
The Harmoni trial showed that the combination delayed cancer progression or death. However, it did not show a statistically significant survival benefit, which the FDA said was needed to support approval, according to Summit.
Summit pointed to later analyses showing consistent survival results across regions, but the findings did not resolve the agency's concerns. "We are disappointed for patients and their families awaiting additional treatment options in this setting," Chairman and Co-CEO Robert Duggan said.
Summit will still study Ivonescimab in other settings, including first-line lung cancer and colorectal cancer.
Capricor has already faced setbacks in its bid to win approval for Deramiocel. The FDA issued a complete response letter in July 2025, asking for more clinical evidence. In July this year, an FDA advisory panel voted 9-3 against the evidence supporting the treatment's effectiveness for Duchenne-related heart muscle disease.
The vote was nonbinding and did not cover Hope-3's main measure of arm and hand function or the treatment's overall benefits and risks, according to Capricor.
文章开头,摘自Yahoo Finance。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (finance.yahoo.com)




